Literature DB >> 7536026

Pancreatic carcinoma.

D M Kelly1, I S Benjamin.   

Abstract

The management of patients with pancreatic carcinoma poses many problems. The diagnosis is usually made late, generally because the patients present late, but it is not unusual to find patients who have had many negative investigations for vague upper abdominal symptoms only to be diagnosed as having pancreatic carcinoma many months later. Staging the disease is equally difficult and often inaccurate. The results of treatment are to date discouraging even in those patients diagnosed early. But the outlook is not totally dismal; in recent years the results for surgical resection of pancreatic lesions have improved; adjuvant treatment may finally be having an effect, although small, on this relentless disease. The most notable inroad made in the management of pancreatic cancer in the last 10 years is the improvement in palliation due to the use of the endoprosthesis. In spite of the poor results we must continue to search actively for more accurate methods of diagnosis and better methods of treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536026     DOI: 10.1093/oxfordjournals.annonc.a059031

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  12 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 2.  Differentiation of mucinous cystic neoplasm and cystic changes associated with pancreatic adenocarcinoma.

Authors:  Tae Hwan Ha; Tae Joo Jeon; Ji Young Park
Journal:  BMJ Case Rep       Date:  2013-11-05

Review 3.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

4.  Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.

Authors:  Lars Boenicke; Kang Chu; Regina Pauls; Claudia Tams; Marie-Luise Kruse; Roland Kurdow; Bodo Schniewind; Arnd Böhle; Bernd Kremer; Holger Kalthoff
Journal:  J Mol Med (Berl)       Date:  2003-03-18       Impact factor: 4.599

Review 5.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

6.  Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.

Authors:  Ralf Wilkowski; Martin Thoma; Rolf Schauer; Andreas Wagner; Volker Heinemann
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

7.  Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.

Authors:  Takayuki Ohguri; Hajime Imada; Katsuya Yahara; Hiroyuki Narisada; Tomoaki Morioka; Keita Nakano; Yukunori Korogi
Journal:  Radiat Med       Date:  2009-01-08

8.  Pain management of patients with unresectable peripancreatic carcinoma.

Authors:  Rutger C I van Geenen; Claudia M G Keyzer-Dekker; Geertjan van Tienhoven; Huug Obertop; Dirk J Gouma
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

9.  A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Authors:  S Cascinu; R R Silva; S Barni; R Labianca; L Frontini; E Piazza; G Pancera; P Giordani; L Giuliodori; M A Pessi; V Fusco; G Luporini; R Cellerino; G Catalano
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

10.  Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.

Authors:  P Corrie; A Mayer; J Shaw; S D'Ath; S Blagden; C Blesing; P Price; N Warner
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.